Fexofenadine Hydrochloride

Phase 2Small molecule

UUniversity Ghent

Fexofenadine Hydrochloride is one of 26 small molecule programs targeting AIN. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AINCompleted

ST-Segment Elevation Myocardial Infarction (STEMI)Recruiting

AINPreclinical

Completed

ST-Segment Elevation Myocardial Infarction (STEMI)Phase 2

Recruiting

Competition

Competitive Landscape

30 competitors in AIN

#DrugCompanyPhaseTrials

Jevtana

Sanofi

Phase 2

1 2

Lynparza

AstraZeneca

Phase 2

1 3

Avastin

Roche

Phase 2

1 4

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 5

Reblozyl

Bristol-Myers Squibb

Phase 2

1 6

GM-CSF

YY-mAbs Therapeutics

Phase 3

1 7

Paraplatin

AAvyxa

Phase 2

2 8

Brukinsa

BBeOne Medicines

Phase 2

1 9

Vepesid

AAvyxa

Phase 2

1 10

Rayos

RRoxane Laboratories

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

ST-Segment Elevation Myocardial Infarction (STEMI)

NCT06548204

Clinical

Trials by Indication[1]

AIN1 trial

Histamine H1/H2 Receptors and Training Adaptations

Completed·UUniversity Ghent·N/A·NCT04450134·19 enrolled

Oral1 trial

Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition

Completed·—·Phase 1·NCT01888718·80 enrolled

ST-segment Elevation Myocardial Infarction (STEMI)1 trial

Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06548204·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Fexofenadine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fexofenadine Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fexofenadine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Ghent company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Ghent

Fexofenadine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

AIN1 trial

Oral1 trial

ST-segment Elevation Myocardial Infarction (STEMI)1 trial

References

Drug Info

Quick Facts

Related News